vs
Side-by-side financial comparison of CuriosityStream Inc. (CURI) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $19.2M, roughly 1.8× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -299.9%, a 280.2% gap on every dollar of revenue. On growth, CuriosityStream Inc. posted the faster year-over-year revenue change (35.8% vs 11.6%). Over the past eight quarters, CuriosityStream Inc.'s revenue compounded faster (26.5% CAGR vs 1.4%).
Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.
CURI vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $34.1M |
| Net Profit | $-3.8M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | -17.6% | -52.4% |
| Net Margin | -19.7% | -299.9% |
| Revenue YoY | 35.8% | 11.6% |
| Net Profit YoY | -34.6% | -232.0% |
| EPS (diluted) | $-0.07 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $19.2M | $34.1M | ||
| Q3 25 | $18.4M | $44.0M | ||
| Q2 25 | $19.0M | $37.9M | ||
| Q1 25 | $15.1M | $30.0M | ||
| Q4 24 | $14.1M | $30.5M | ||
| Q3 24 | $12.6M | $38.8M | ||
| Q2 24 | $12.4M | $42.8M | ||
| Q1 24 | $12.0M | $33.1M |
| Q4 25 | $-3.8M | $-102.2M | ||
| Q3 25 | $-3.7M | $-33.1M | ||
| Q2 25 | $784.0K | $-37.3M | ||
| Q1 25 | $319.0K | $-23.5M | ||
| Q4 24 | $-2.8M | $-30.8M | ||
| Q3 24 | $-3.1M | $-32.1M | ||
| Q2 24 | $-2.0M | $23.8M | ||
| Q1 24 | $-5.0M | $-37.4M |
| Q4 25 | -17.6% | -52.4% | ||
| Q3 25 | -24.5% | -34.6% | ||
| Q2 25 | 2.5% | -64.3% | ||
| Q1 25 | 0.5% | -110.8% | ||
| Q4 24 | -27.4% | -102.4% | ||
| Q3 24 | -25.8% | -67.8% | ||
| Q2 24 | -20.6% | -65.7% | ||
| Q1 24 | -30.4% | -101.9% |
| Q4 25 | -19.7% | -299.9% | ||
| Q3 25 | -20.4% | -75.2% | ||
| Q2 25 | 4.1% | -98.2% | ||
| Q1 25 | 2.1% | -78.2% | ||
| Q4 24 | -19.9% | -100.8% | ||
| Q3 24 | -24.3% | -82.7% | ||
| Q2 24 | -16.4% | 55.6% | ||
| Q1 24 | -42.0% | -112.8% |
| Q4 25 | $-0.07 | $-7.02 | ||
| Q3 25 | $-0.06 | $-3.82 | ||
| Q2 25 | $0.01 | $-4.32 | ||
| Q1 25 | $0.01 | $-2.77 | ||
| Q4 24 | $-0.05 | $-2.33 | ||
| Q3 24 | $-0.06 | $-3.85 | ||
| Q2 24 | $-0.04 | $-2.97 | ||
| Q1 24 | $-0.09 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.3M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $41.5M | $-292.9M |
| Total Assets | $75.7M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.3M | $60.5M | ||
| Q3 25 | $27.8M | $37.7M | ||
| Q2 25 | $28.1M | $38.7M | ||
| Q1 25 | $33.4M | $38.8M | ||
| Q4 24 | $32.1M | $62.5M | ||
| Q3 24 | $33.2M | $72.8M | ||
| Q2 24 | $39.5M | $84.8M | ||
| Q1 24 | $38.8M | $30.6M |
| Q4 25 | $41.5M | $-292.9M | ||
| Q3 25 | $47.2M | $-269.3M | ||
| Q2 25 | $49.8M | $-238.9M | ||
| Q1 25 | $58.1M | $-205.9M | ||
| Q4 24 | $57.8M | $-186.0M | ||
| Q3 24 | $62.2M | $-159.6M | ||
| Q2 24 | $64.8M | $-132.1M | ||
| Q1 24 | $67.0M | $-169.0M |
| Q4 25 | $75.7M | $108.4M | ||
| Q3 25 | $74.7M | $96.2M | ||
| Q2 25 | $78.7M | $104.9M | ||
| Q1 25 | $85.3M | $127.7M | ||
| Q4 24 | $86.2M | $164.4M | ||
| Q3 24 | $87.6M | $189.5M | ||
| Q2 24 | $90.9M | $214.0M | ||
| Q1 24 | $94.6M | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.0M | $-11.8M |
| Free Cash FlowOCF − Capex | $3.9M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.0M | $-11.8M | ||
| Q3 25 | $4.4M | $-5.9M | ||
| Q2 25 | $2.8M | $-18.7M | ||
| Q1 25 | $1.9M | $-39.0M | ||
| Q4 24 | $3.0M | $-25.8M | ||
| Q3 24 | $2.3M | $-19.5M | ||
| Q2 24 | $2.2M | $-38.5M | ||
| Q1 24 | $666.0K | $-43.7M |
| Q4 25 | $3.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-43.9M |
| Q4 25 | 20.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -132.6% |
| Q4 25 | 0.1% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.5% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.0% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 6.03× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURI
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
